tgDCC-E1A gene therapy - Targeted Genetics

Drug Profile

tgDCC-E1A gene therapy - Targeted Genetics

Alternative Names: E1A gene therapy; HER-2/neu inhibitor; LF 160519; RGG 0853

Latest Information Update: 14 Mar 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Targeted Genetics
  • Developer Targeted Genetics; Targeted Genetics Corporation
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Head and neck cancer; Ovarian cancer

Most Recent Events

  • 14 Aug 2002 Suspended - Phase-I for Ovarian cancer in USA (Intratumoural)
  • 07 Aug 2002 Suspended - Phase-I for Ovarian cancer in Europe (Intratumoural)
  • 07 Aug 2002 Suspended - Phase-II for Head and neck cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top